PENAMBATAN MOLEKUL DAN PREDIKSI UJI TOKSISITAS PADA SENYAWA TURUNAN INHIBITOR GATA-2 SEBAGAI PENINGKAT TRANSKRIPSI ERITROPOIESIS
Keywords:
Anemia, GATA-2, Proliferation, Erythrosite, Pyrrothiogatain DerivativeAbstract
Anemia is a condition in which the number of red blood cells or the amount of hemoglobin, a protein responsible for transporting oxygen throughout the body, is below normal. The condition of chronic kidney disease causes a decrease in hemoglobin levels in the body so that it affects the proliferation of red blood cells. The search for compounds to stimulate the process of red blood cell proliferation without involving erythropoietin was carried out. Pyrrotiogatain compounds are believed to increase the proliferation of red blood cells, but are reported to have serious toxicity. Then modification of the molecule is carried out to find the effectiveness which has lower toxicity. Several pyritiogartain derivatives have been produced which are effective with molecular tethering and determination of the productive toxicity
Downloads
References
Bakta, I Made. 2006. Hematologi Klinik Ringkas. Penerbit Kedokteran EGC.
Gaine, M.E., et al. 2017. GATA2 regulates the erythropoietin receptor in t(12;21) ALL. Oncotarget, 8(39):66061-66074.
Kim, S.I., & Bresnick, E.H. 2007. Transcriptional control of erythropoiesis: emerging mechanisms and principles. Oncogene, 26:6777-6794.
La Ferla, K., et al. 2002. Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF-kB.
Moriguchi, T. & Yamamoto, M. 2014. A regulatory network governing Gata1 and Gata2 gene trancription orchesrates erythroid lineage differentiation. Int.
J. Hematol, 100:417-424.
Nomura, S., et al. 2019. Pyrrothiogatain acts as inhibitor of GATA family proteins and inhibits Th2 cell differentiation in vitro. Scintific Reports, 9:17335.
Suzuki, M., et al. 2011. Transcriptional regulation by GATA1 and GATA2 during erythropoiesis. Int. J, Hematol, 93:150-155.
Topliss, John G. 1972. Utilization of operational schemes for analog synthesis in drug design. Journal of Medicinal Chemistry, 15(10):1006-1010
